SCHEMBL19084661

SCHEMBL19084661

N#Cc1ccc(-c2cc(=O)n3nc(C4CC4)c(-c4ccc(Cl)cc4)c3[nH]2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ARF6 P62330 9/20 0.52
PSD A5PKW4 4/20 0.48
PLAT P00750 2/20 0.40
KIT P10721 1/20 0.38
KDM1A O60341 1/20 0.37
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 2/20 0.35
MEN1 O00255 1/20 0.35
LMNA P02545 1/20 0.35
GLA P06280 1/20 0.35
GAA P10253 1/20 0.35
HPGD P15428 1/20 0.35
CRHBP P24387 1/20 0.35
HTT P42858 1/20 0.35
KMT2A Q03164 1/20 0.35
CRHR2 Q13324 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
MAP2 P11137 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19084566 0.93 PSD (0.52) ARF6PSDPLATKITKDM1A
SCHEMBL19084514 0.90 PSD (0.51) ARF6PSDPLATMEN1LMNA
SCHEMBL10275640 0.89 ARF6 (0.53) ARF6PSDPLATKITKDM1A
SCHEMBL19084609 0.84 PSD (0.48) ARF6PSDPLAT
SCHEMBL19084517 0.83 PSD (0.49) ARF6PSDPLAT
SCHEMBL19084619 0.83 ARF6 (0.52) ARF6PSDPLATALDH1A1MEN1
SCHEMBL10275663 0.82 ARF6 (0.47) ARF6PSDPLATKITKDM1A
SCHEMBL19084510 0.81 PSD (0.51) ARF6PSDPLAT
SCHEMBL17298733 0.80 ARF6 (0.63) ARF6PSDPLATKDM4EALDH1A1
SCHEMBL10275602 0.77 ARF6 (0.39) ARF6PSDPLATKITKDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10849901-B2 Arf6 inhibitors and methods of synthesis and use thereof NAVIGEN, INC. (US) 2020-12-01 US disclosed
US-20170189405-A1 ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF NAVIGEN, INC. (US) 2017-07-06 US disclosed
US-20170189405-A1 ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF NAVIGEN, INC. (US) 2017-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170189405-A1 ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF ARF6, ARF1, ARFIP2 ARF6 1/4885PSD 211/4885PLAT 3989/4885
US-10849901-B2 Arf6 inhibitors and methods of synthesis and use thereof ARF6, ARF1, ARFIP2 ARF6 1/4885PSD 211/4885PLAT 3989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.